| __timestamp | MiMedx Group, Inc. | Protagonist Therapeutics, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 7050000 | 7459000 |
| Thursday, January 1, 2015 | 8413000 | 11831000 |
| Friday, January 1, 2016 | 12038000 | 25705000 |
| Sunday, January 1, 2017 | 17900000 | 46181000 |
| Monday, January 1, 2018 | 15765000 | 59497000 |
| Tuesday, January 1, 2019 | 11140000 | 65003000 |
| Wednesday, January 1, 2020 | 11715000 | 74506000 |
| Friday, January 1, 2021 | 17344000 | 126006000 |
| Saturday, January 1, 2022 | 22829000 | 126215000 |
| Sunday, January 1, 2023 | 12665000 | 120161000 |
Data in motion
In the competitive world of biotechnology, research and development (R&D) spending is a critical indicator of a company's commitment to innovation. Over the past decade, Protagonist Therapeutics, Inc. and MiMedx Group, Inc. have demonstrated contrasting strategies in their R&D investments. From 2014 to 2023, Protagonist Therapeutics increased its R&D spending by over 1,500%, peaking in 2022 with a staggering 1.26 billion dollars. This aggressive investment reflects their strategic focus on pioneering new therapies. In contrast, MiMedx Group's R&D expenses grew by approximately 224% during the same period, reaching their highest in 2022. This more conservative approach suggests a balanced strategy, possibly focusing on optimizing existing products. The data highlights the diverse paths companies take in the biotech sector, emphasizing the importance of R&D in driving future growth and innovation.
Who Prioritizes Innovation? R&D Spending Compared for Novartis AG and MiMedx Group, Inc.
R&D Spending Showdown: Bristol-Myers Squibb Company vs MiMedx Group, Inc.
Research and Development Expenses Breakdown: Teva Pharmaceutical Industries Limited vs MiMedx Group, Inc.
Who Prioritizes Innovation? R&D Spending Compared for Biogen Inc. and Protagonist Therapeutics, Inc.
Research and Development Investment: Biogen Inc. vs MiMedx Group, Inc.
R&D Insights: How BeiGene, Ltd. and MiMedx Group, Inc. Allocate Funds
Research and Development Investment: Dr. Reddy's Laboratories Limited vs MiMedx Group, Inc.
Comparing Innovation Spending: Ascendis Pharma A/S and Protagonist Therapeutics, Inc.
Grifols, S.A. vs Protagonist Therapeutics, Inc.: Strategic Focus on R&D Spending
Research and Development: Comparing Key Metrics for Amneal Pharmaceuticals, Inc. and MiMedx Group, Inc.
Comparing Innovation Spending: Protagonist Therapeutics, Inc. and Agios Pharmaceuticals, Inc.
Research and Development Investment: Geron Corporation vs MiMedx Group, Inc.